Table I.
Experimental intestinal anaphylaxis in iFABPp-IL-9Tg mice is IL-4Rα and STAT6 dependent
| Experimental group | Treatment | % Diarrhea occurrence (on day 9) |
Mast cells/HPF (mean ± SEM) |
Serum mMCP-1 (ng/ml; mean ± SEM) |
|
|---|---|---|---|---|---|
| BALB/c WT | 0.68 ± 0.07 | 27.46 ± 3.90 | |||
| BALB/c WT | Vehicle | OVA | 0/12 | 0.13 ± 0.01 | 23.91 ± 3.64 |
| BALB/c WT | OVA | OVA | 14/14 | 31.29 ± 0.57 | 16,260.57 ± 4,817.16 |
| IFABPp-IL-9Tg | 7.20 ± 0.33 | 152.50 ± 1.65 | |||
| IFABPp-IL-9Tg | Vehicle | OVA | 15/15 | 28.68 ± 0.82 | 19,319.34 ± 3,961.13 |
| IFABPp-IL-9Tg | OVA | OVA | 12/16 | 97.52 ± 2.19 | 83,399.48 ± 7,880.93 |
| IFABPp-IL-9Tg (IL-9Tg)/ STAT6−/− | 2.87 ± 0.31 | 37.90 ± 1.60 | |||
| IL-9Tg/STAT6−/− | Vehicle | OVA | 0/9 | 2.93 ± 0.21 | 870.30 ± 191.92 |
| IL-9Tg/STAT6−/− | OVA | OVA | 1/8 | 11.91 ± 0.66 | 1,168.17 ± 268.46 |
| IFABPp-IL-9Tg (IL-9Tg)/IL-4Rα−/− | 2.75 ± 0.01 | 26.20 ± 0.90 | |||
| IL-9Tg/IL-4Rα−/− | Vehicle | OVA | 0/10 | 3.04 ± 0.14 | 100.26 ± 15.01 |
| IL-9Tg/IL-4Rα−/− | OVA | OVA | 0/9 | 8.05 ± 0.19 | 808.07 ± 154.09 |
Diarrhea, mean number of mast cells per high power field of view and serum mMCP-1 for iFABPp-IL-9Tg and BALB/c WT mice deficient in IL-4Rα or STAT6 following intraperitoneal sensitization with OVA or saline and nine intragastric OVA or saline challenges.